About this Author
DBL%20Hendrix%20small.png College chemistry, 1983

Derek Lowe The 2002 Model

Dbl%20new%20portrait%20B%26W.png After 10 years of blogging. . .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
Not Voodoo

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
A New Merck, Reviewed
Liberal Arts Chemistry
Electron Pusher
All Things Metathesis
C&E News Blogs
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
BBSRC/Douglas Kell
Realizations in Biostatistics
ChemSpider Blog
Organic Chem - Education & Industry
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
The Curious Wavefunction
Natural Product Man
Fragment Literature
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Eye on FDA
Chemical Forums
Symyx Blog
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa

Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
Gene Expression (I)
Gene Expression (II)
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
Cosmic Variance
Biology News Net

Medical Blogs
DB's Medical Rants
Science-Based Medicine
Respectful Insolence
Diabetes Mine

Economics and Business
Marginal Revolution
The Volokh Conspiracy
Knowledge Problem

Politics / Current Events
Virginia Postrel
Belmont Club
Mickey Kaus

Belles Lettres
Uncouth Reflections
Arts and Letters Daily
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« Most Picturesque Biopharma Location? | Main | Well, Okay: The Ugliest Biopharma Sites? »

October 12, 2010

Exelixis Grabs A Life Preserver

Email This Entry

Posted by Derek

I was talking with some folks about this just last night - looks like Exelixis has rounded up some more money by signing a revised deal with BMS. They've been having a rough time out there recently, so I'm glad that there's a lifeline available. More on this as things become clearer. . .

Comments (5) + TrackBacks (0) | Category: Business and Markets


1. AlchemistOrganique on October 12, 2010 2:10 PM writes...

Just read the C&E News article online. OMG, is that Tarceva drawn on the hood sash? I'm assuming that was drawn for the publicity shot rather than representative of a current analog project!

Permalink to Comment

2. watcher on October 12, 2010 7:24 PM writes...

I don't know why you are feeling so generous and sympathetic for the company...certainly it's always bad for individuals who get caught at no fault of their own.

Yet, Excelixis make promises, promises, promises yet don't come close to delivering uniqueness or value. They've taken millions in deal funding, not to return much to the partner companies. They keep pushing the same compounds, knocking on door after door, one company to another. You'd think after a while they'd get the message that the compounds simply don't look good enough to take them further.

The strongest survive; the weaker wither away (well normally, but not always).

Permalink to Comment

3. Osaka on October 13, 2010 5:11 AM writes...

In almost any non-greedy selection or optimization algorithm, certain non-optimal candidates must be maintained to prevent stagnation. You can set the bar arbitrarily high for what can or cannot be used, sure, but you get an exponential back off on actual results. It actually makes more sense to have variety than to have all the strongest set, which is exactly how natural selection works.

So your statement that the "strongest survive" is very suspect; the strongest are only strongest today, and even then it's hard to tell exactly what 'strongest" means. If the population as a whole wants to remain as fit as possible, it must have variety, especially some amount of variety below the watermark.

The "weaker" do not wither away; they serve as containers for variety for when the "strong" are the "weak", ie, when times change.

Permalink to Comment

4. Anonymous on October 13, 2010 7:26 AM writes...

Just heard King Pharma has been 'assimilated'. Yet another one bites the dust

Permalink to Comment

5. Resistancei is futile! on October 13, 2010 8:33 AM writes...

Nooo!!! The Pfi-Borg strikes again!

Permalink to Comment


Remember Me?


Email this entry to:

Your email address:

Message (optional):

The Last Post
The GSK Layoffs Continue, By Proxy
The Move is Nigh
Another Alzheimer's IPO
Cutbacks at C&E News
Sanofi Pays to Get Back Into Oncology
An Irresponsible Statement About Curing Cancer
Oliver Sacks on Turning Back to Chemistry